A student-run resource for reliable reports on the latest law and technology news

Archive for the ‘Pharmaceuticals’ Category

Illinois District Court Opinion Shows Uncertainty of the Economics of ANDA litigation

By Yaping Zhang – Edited by Mengyi Wang

The Northern District of Illinois just laid down a Hatch-Waxman opinion, holding that the Mylan Pharmaceuticals Inc. infringed the patent No. 727 Patent held by Medicines Company. Patently-O published a study that demonstrates ANDA Paragraph (iv) cases have increasingly settled, reducing consumer surplus. The case suggests that there are potentially more complicated calculus and players embedded in ANDA litigations than originally thought.

Read More...

Posted On Nov - 10 - 2014 Add Comments READ FULL POST

Federal Circuit Flash Digest: News in Brief 

By Amanda Liverzani

Non-Infringement Decision on Hospital Bed Patents Reversed for Erroneous Claim Construction

Patents for Eyelash Growth Treatment Invalidated Based on Obviousness

Constitutionality of “First-Inventor-to-File” Regime Still Undecided

Read More...

Posted On Jul - 6 - 2014 Comments Off READ FULL POST

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.

Read More...

Posted On Mar - 13 - 2014 Comments Off READ FULL POST

Flash Digest: News In Brief
By James Grace

Hershey’s Opposes Mars’ Attempt to Register a Snickers’ Cross-Section as a Design Mark

Medtronic v. Boston Scientific – Oral Argument

Proposed Tweak to Law Would Pull Shield From Generic-Drug Makers

Read More...

Posted On Nov - 10 - 2013 Comments Off READ FULL POST

Routine High-Throughput Screening is Undue Experimentation, Federal Circuit Holds

Wyeth v. Abbott Labs
By Kathleen McGuinness – Edited by Alex Shank

The Federal Circuit upheld the invalidity of patents claiming the use of rapamycin to treat restenosis, the renarrowing of an artery following angioplasty. The court held that “routine experimentation” to discover species of compounds within a claimed genus could constitute “undue experimentation,” since the discovery may require screening tens of thousands of compounds without any guidance from the patent.

Read More...

Posted On Jul - 5 - 2013 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
Photo By: archie4oz - CC BY 2.0

Silk Road 2.0 Takedo

  [caption id="attachment_4363" align="alignleft" width="150"] Photo By: archie4oz - CC BY ...

Unknown

Federal Circuit Flas

By Ken Winterbottom Motion to Dismiss in Hulu Patent Infringement Suit ...

GOOGLE_APTHDVR_1268416f

Spain Passes a “Go

By Michael Shammas — Edited by Yixuan Long Amendments to the ...

radio-wireless-tower-clip-art_resized

Federal Circuit Tigh

By Kathleen McGuinness – Edited by Sabreena Khalid Azure Networks, LLC ...

Unknown

Flash Digest: News i

By Viviana Ruiz Russia’s Intellectual Property Court affirms denial of Ford's ...